Page 8 - Kymab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kymab Today - Breaking & Trending Today

Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Quarterly Earnings Results

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) announced its earnings results on Friday. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.44) by $0.47, Briefing.com reports. The firm had revenue of $31.45 million for the quarter, compared to the consensus estimate of $20.35 million. Y-mAbs Therapeutics had a negative net margin […] ....

New York , United States , Millennium Management , Y Mabs Therapeutics Company Profile , Y Mabs Therapeutics Inc , Canaccord Genuity Group , Morgan Stanley , Blackrock Inc , Polar Capital Holdings Plc , Capital Management , Y Mabs Therapeutics , Get Rating , Abs Therapeutics , Capital Holdings Plc , Street Corp , Genuity Group , Thomas Gad , Y Mabs Therapeutics Daily , Nasdaq Ymab ,

Y-mAbs Therapeutics (NASDAQ:YMAB) Releases Quarterly Earnings Results, Beats Estimates By $0.47 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) released its quarterly earnings results on Friday. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.44) by $0.47, Briefing.com reports. Y-mAbs Therapeutics had a negative net margin of 146.43% and a negative return on equity of 72.26%. The business had revenue of $31.45 million […] ....

New York , United States , Y Mabs Therapeutics Inc , Polar Capital Holdings Plc , Capital Management , Morgan Stanley , Canaccord Genuity Group , Millennium Management , Y Mabs Therapeutics , Get Rating , Abs Therapeutics , Capital Holdings Plc , Street Corp , Genuity Group , Thomas Gad , Y Mabs Therapeutics Daily , Nasdaq Ymab ,

Mirae Asset Global Investments Co. Ltd. Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,186 shares of the company’s stock, valued at approximately $169,000. Other hedge […] ....

United States , Dekabank Deutsche Girozentrale , Morgan Stanley , Kempen Co , Y Mabs Therapeutics Inc , Financial Corp , Connor Clark Lunn Investment Management Ltd , Exchange Commission , Jpmorgan Chase Co , Mirae Asset Global Investments Co , Canaccord Genuity Group , Mirae Asset Global Investments , Y Mabs Therapeutics , Get Rating , Bank Deutsche Girozentrale , Lunn Investment Management , Strs Ohio , Abs Therapeutics , Visit Holdingschannel , Y Mabs Therapeutics Daily , Nasdaq Ymab , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among […] ....

United States , Y Mabs Therapeutics Company Profile Get Rating , Polar Capital Holdings Plc , Y Mabs Therapeutics Inc , Blackrock Inc , Dimensional Fund Advisors , Y Mabs Therapeutics , Get Rating , Capital Holdings Plc , Street Corp , Abs Therapeutics , Abs Therapeutics Company Profile , Nasdaq Ymab ,

Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $31.60

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price […] ....

United States , Hong Kong , Dekabank Deutsche Girozentrale , Y Mabs Therapeutics Company Profile Get Rating , Y Mabs Therapeutics Inc , Hong Kong Ltd , Royal Bank , Y Mabs Therapeutics , Get Rating , Marketbeat Ratings , Abs Therapeutics , Kong Ltd , Bank Deutsche Girozentrale , Abs Therapeutics Company Profile , Nasdaq Ymab ,